DexTech Medical AB (XSAT:DEX) Change In Receivables: kr0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:DEX DexTech Medical AB XSAT:DEX
23 GF Score
Price kr10.10
! 2 Warning Signs
View Full Analysis

What is DexTech Medical AB Change In Receivables?

DexTech Medical AB XSAT:DEX 23 Change In Receivables is kr0.00 Mil as of Mar. 2026. GuruFocus rates XSAT:DEX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

DexTech Medical AB's change in receivables for the quarter that ended in Mar. 2026 was kr0.00 Mil. It means DexTech Medical AB's Accounts Receivable stayed the same from Dec. 2025 to Mar. 2026 .

DexTech Medical AB's change in receivables for the fiscal year that ended in Jun. 2025 was kr0.16 Mil. It means DexTech Medical AB's Accounts Receivable declined by kr0.16 Mil from Jun. 2024 to Jun. 2025 .

DexTech Medical AB's Accounts Receivable for the quarter that ended in Mar. 2026 was kr0.68 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. DexTech Medical AB's liquidation value for the three months ended in Mar. 2026 was kr10.09 Mil.

DexTech Medical AB  (XSAT:DEX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

DexTech Medical AB's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.679/0*91
=

2. In Ben Graham's calculation of liquidation value, DexTech Medical AB's accounts receivable are only considered to be worth 75% of book value:

DexTech Medical AB's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=10.118-0.535+0.75 * 0.679+0.5 * 0
=10.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexTech Medical AB Change In Receivables Related Terms

DexTech Medical AB Change In Receivables Historical Data

* Premium members only.

The historical data trend for DexTech Medical AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexTech Medical AB Change In Receivables Chart

DexTech Medical AB Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.25 -0.03 -0.05 0.16

DexTech Medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSAT:DEX
23GF Score
DexTech Medical AB XSAT:DEX
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexTech Medical AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of kr0.00 Mil mean?
DexTech Medical AB (XSAT:DEX) has a Change In Receivables of kr0.00 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for DexTech Medical AB and its competitors.
Is DexTech Medical AB's Change In Receivables too high?
DexTech Medical AB's current Change In Receivables is kr0.00 Mil. Overall, DexTech Medical AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does DexTech Medical AB's Change In Receivables compare to VRTX and REGN?
DexTech Medical AB's Change In Receivables of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for DexTech Medical AB and its competitors. DexTech Medical AB's current Change In Receivables is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexTech Medical AB stock overvalued right now?
DexTech Medical AB (XSAT:DEX) has a current Change In Receivables of kr0.00 Mil. The current Change In Receivables is kr0.00 Mil. DexTech Medical AB's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For DexTech Medical AB (XSAT:DEX), the current Change In Receivables is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DexTech Medical AB Business Description

Address Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB is a Swedish research company specializing in drug development for urological oncology, with a prominent focus on prostate cancer. The company develops drug candidates using a proprietary carbohydrate platform, advancing treatments aimed at castration-resistant prostate cancer and related conditions. Its operations center on research, development, and licensing of these drug candidates. It has four drug candidates: OsteoDex, SomaDex, PSMA-binding conjugates, and GuaDex.
23GF Score

Get the complete analysis for XSAT:DEX

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.10
Price